These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 12186399

  • 1. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K, Sato K, Kamohara M, Kaku S, Kawasaki T, Yano S, Iizumi Y.
    Biol Pharm Bull; 2002 Aug; 25(8):1006-12. PubMed ID: 12186399
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects.
    Harder S, Kirchmaier CM, Krzywanek HJ, Westrup D, Bae JW, Breddin HK.
    Circulation; 1999 Sep 14; 100(11):1175-81. PubMed ID: 10484537
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys.
    Suzuki K, Sakai Y, Hisamichi N, Taniuchi Y, Sato K, Terazaki C, Kaku S, Kawasaki T, Yano S, Inagaki O, Masuho Y.
    Eur J Pharmacol; 1997 Oct 08; 336(2-3):169-76. PubMed ID: 9384230
    [Abstract] [Full Text] [Related]

  • 4. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C.
    Blood; 1998 Nov 01; 92(9):3240-9. PubMed ID: 9787160
    [Abstract] [Full Text] [Related]

  • 5. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 01; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 6. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 01; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 7. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S, Kawasaki T, Hisamichi N, Sakai Y, Taniuchi Y, Inagaki O, Yano S, Suzuki K, Terazaki C, Masuho Y, Satoh N, Takenaka T, Yanagi K, Ohshima N.
    Thromb Haemost; 1996 Apr 01; 75(4):679-84. PubMed ID: 8743199
    [Abstract] [Full Text] [Related]

  • 8. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 9. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA, Schrör K.
    Blood; 2001 Sep 01; 98(5):1619-21. PubMed ID: 11520817
    [Abstract] [Full Text] [Related]

  • 10. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 11. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV.
    Circulation; 1995 Mar 01; 91(5):1354-62. PubMed ID: 7867173
    [Abstract] [Full Text] [Related]

  • 12. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins.
    Tam SH, Sassoli PM, Jordan RE, Nakada MT.
    Circulation; 1998 Sep 15; 98(11):1085-91. PubMed ID: 9736595
    [Abstract] [Full Text] [Related]

  • 13. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP, Tien N, McCarty OJ, Plymire D, Mousa SA, Konstantopoulos K.
    Arterioscler Thromb Vasc Biol; 2001 Jan 15; 21(1):149-56. PubMed ID: 11145947
    [Abstract] [Full Text] [Related]

  • 14. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May 15; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 15. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 May 15; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 16. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 15; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 17. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR.
    Crit Care Med; 2002 May 15; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [Abstract] [Full Text] [Related]

  • 18. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin.
    Lele M, Sajid M, Wajih N, Stouffer GA.
    Circulation; 2001 Jul 31; 104(5):582-7. PubMed ID: 11479257
    [Abstract] [Full Text] [Related]

  • 19. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ.
    J Thromb Thrombolysis; 2002 Aug 31; 14(1):15-24. PubMed ID: 12652146
    [Abstract] [Full Text] [Related]

  • 20. Von Willebrand factor can support platelet aggregation via interaction with activated GPIIb-IIIa and GPIb.
    Naimushin YA, Mazurov AV.
    Platelets; 2004 Nov 31; 15(7):419-25. PubMed ID: 15745313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.